Potential role of neurogenic inflammatory factors in the pathogenesis of vitiligo

Journal of Cutaneous Medicine and Surgery

Volumn 16, Issue 4, 2012, Pages 230-244

  Yu, Richard ^a,b   Huang, Yuanshen ^a,b   Zhang, Xuejun ^a,b   Zhou, Youwen ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CALCITONIN GENE RELATED PEPTIDE; CATECHOLAMINE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; DOPAMINE; IMMUNOLOGIC FACTOR; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; NEUROGENIC INFLAMMATORY FACTOR; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTROPHIN; NEUROTROPHIN RECEPTOR P75; NORADRENALIN; PIMECROLIMUS; PROTEIN TYROSINE KINASE A; PSORALEN; TACROLIMUS; UNCLASSIFIED DRUG;

ACNE; COGNITIVE THERAPY; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MELANOCYTE; MENSTRUAL IRREGULARITY; MENTAL STRESS; NERVOUS SYSTEM; PATHOGENESIS; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN SECRETION; PSYCHOEDUCATION; PUVA; REVIEW; SIDE EFFECT; SKIN; STRESS MANAGEMENT; ULTRAVIOLET B RADIATION; UPREGULATION; VITILIGO; WEIGHT GAIN;

CALCITONIN GENE-RELATED PEPTIDE; CATECHOLAMINES; DISEASE SUSCEPTIBILITY; HUMANS; MELANOCYTES; NERVE GROWTH FACTOR; NEUROGENIC INFLAMMATION; NEUROPEPTIDE Y; VITILIGO;

EID: 84864153310     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2011.11068     Document Type: Review

References (187)

1. Abu Tahir M, Pramod K, Ansari SH, et al. Current remedies for vitiligo. Autoimmun Rev 2010;9:516-20, doi:10.1016/j.autrev.2010.02.013.
2. Grimes PE. New insights and new therapies in vitiligo. JAMA 2005;293:730-5, doi:10.1001/jama.293.6.730. (Pubitemid 40216043)
3. Whitton ME, Ashcroft DM, Gonzalez U. Therapeutic interventions for vitiligo. J Am Acad Dermatol 2008;59:713-7, doi:10.1016/j.jaad.2008.06.023.
4. Porter JR, Beuf AH. Racial variation in reaction to physical stigma: a study of degree of disturbance by vitiligo among black and white patients. J Health Soc Behav 1991;32:192-204, doi:10.2307/2137152.
5. Thompson AR, Kent G, Smith JA. Living with vitiligo: dealing with difference. Br J Health Psychol 2002;7:213-25, doi:10.1348/135910702169457. (Pubitemid 34555867)
6. Porter JR, Beuf AH, Lerner A, et al. Psychosocial effect of vitiligo: a comparison of vitiligo patients with "normal" control subjects, with psoriasis patients, and with patients with other pigmentary disorders. J Am Acad Dermatol 1986;15:220-4, doi:10.1016/S0190-9622(86)70160-6. (Pubitemid 16070350)
7. Kent G, Al'Abadie M. Psychologic effects of vitiligo: a critical incident analysis. J Am Acad Dermatol 1996;35:895-8, doi:10.1016/S0190-9622(96)90112-7. (Pubitemid 26422112)
8. Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med 2010;123:183 e181-9, doi:10.1016/j.amjmed.2009.06.030.
9. Deretzi G, Kountouras J, Koutlas E, et al. Familial prevalence of autoimmune disorders in multiple sclerosis in northern Greece. Mult Scler 2010;16:1091-101, doi:10.1177/1352458510375708.
10. Kocer B, Nazliel B, Oztas M, et al. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report. Eur J Neurol 2009;16:e78-9, doi:10.1111/j.1468-1331.2009.02563.x.
11. Ramagopalan SV, Dyment DA, Valdar W, et al. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 2007;6:604-10, doi:10.1016/S1474-4422(07)70132-1. (Pubitemid 46921044)
12. Rashtak S, Pittelkow MR. Skin involvement in systemic autoimmune diseases. Curr Dir Autoimmun 2008;10:344-58, doi:10.1159/000131754.
13. Sabate M, Bosch A, Pedros C, et al. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease. Ann Pharmacother 1999;33:1228-9, doi:10.1345/aph.19090.
14. Varoglu AO, Kocaturk I, Tatar A. Prothrombin G20210A mutation, hypogonadotropic hypogonadism, and generalized vitiligo-related ischemic stroke in a young adult. Int J Neurosci 2010;120:451-3, doi:10.3109/00207451003797702.
15. Nikiforidis GC, Tsambaos DG, Karamitsos DS, et al. Abnormalities of the auditory brainstem response in vitiligo. Scand Audiol 1993;22:97-100, doi:10.3109/01050399309046024. (Pubitemid 23139823)
16. Yacubian EM, Rosemberg S, Garrido Neto TL, et al. Rasmussen encephalitis associated with segmental vitiligo of the scalp: clinicopathologic report. J Child Neurol 2001;16:374-7, doi:10.1177/088307380101600513. (Pubitemid 32547305)
17. Rezaei N, Gavalas NG, Weetman AP, et al. Autoimmunity as an aetiological factor in vitiligo. J Eur Acad Dermatol Venereol 2007;21:865-76, doi:10.1111/j.1468-3083.2007.02228.x. (Pubitemid 47103715)
18. Yu HS. Melanocyte destruction and repigmentation in vitiligo: a model for nerve cell damage and regrowth. J Biomed Sci 2002;9:564-73, doi:10.1007/BF02254984.
19. Dell'anna ML, Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res 2006;19:406-11, doi:10.1111/j.1600-0749.2006.00333.x. (Pubitemid 44326402)
20. Gauthier Y, Cario Andre M, Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003;16:322-32, doi:10.1034/j.1600-0749. 2003.00070.x.
21. Elenkov IJ, Wilder RL, Chrousos GP, et al. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000;52:595-638.
22. Downing JE, Miyan JA. Neural immunoregulation: emerging roles for nerves in immune homeostasis and disease. Immunol Today 2000;21:281-9, doi:10.1016/S0167-5699(00)01635-2. (Pubitemid 30333302)
23. Straub RH, Westermann J, Scholmerich J, et al. Dialogue between the CNS and the immune system in lymphoid organs. Immunol Today 1998;19:409-13, doi:10.1016/S0167-5699(98)01297-3. (Pubitemid 28389702)
24. Blalock JE, Weigent DA. Pituitary control of immune cells. Immunol Today 1994;15:39, doi:10.1016/0167-5699(94)90205-4.
25. Besedovsky HO, del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev 1996;17:64-102. (Pubitemid 26061368)
26. Madden KS, Felten DL. Experimental basis for neural-immune interactions. Physiol Rev 1995;75:77-106.
27. Yu XJ, Li CY, Xu YH, et al. Calcitonin gene-related peptide increases proliferation of human HaCaT keratinocytes by activation of MAP kinases. Cell Biol Int 2009;33:1144-8, doi:10.1016/j.cellbi.2009.07.003.
28. Gruber JV, Holtz R. Examining communication between ultraviolet (UV)-damaged cutaneous nerve cells and epidermal keratinocytes in vitro. Toxicol Ind Health 2009;25:225-30, doi:10.1177/0748233709103412.
29. Al'Abadie MS, Senior HJ, Bleehen SS, et al. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994;131:160-5, doi:10.1111/j.1365- 2133.1994.tb08486.x. (Pubitemid 24251486)
30. Hristakieva E, Lazarova R, Lazarov N, et al. Markers for vitiligo related neuropeptides in human skin nerve fibers. Acta Med Croatica 2000;54:53-7.
31. Liu PY, Bondesson L, Lontz W, et al. The occurrence of cutaneous nerve endings and neuropeptides in vitiligo vulgaris: a casecontrol study. Arch Dermatol Res 1996;288:670-5, doi:10.1007/BF02505276. (Pubitemid 26377462)
32. Tu C, Zhao D, Lin X. Levels of neuropeptide-Y in the plasma and skin tissue fluids of patients with vitiligo. J Dermatol Sci 2001;27:178-2, doi:10.1016/S0923-1811(01)00134-7.
33. Morrone A, Picardo M, de Luca C, et al. Catecholamines and vitiligo. Pigment Cell Res 1992;5:65-9, doi:10.1111/j.1600-0749.1992.tb00003.x.
34. Cucchi ML, Frattini P, Santagostino G, et al. Catecholamines increase in the urine of non-segmental vitiligo especially during its active phase. Pigment Cell Res 2003;16:111-6, doi:10.1034/j.1600-0749.2003.00015.x. (Pubitemid 36596956)
35. Cucchi ML, Frattini P, Santagostino G, et al. Higher plasma catecholamine and metabolite levels in the early phase of nonsegmental vitiligo. Pigment Cell Res 2000;13:28-32, doi:10.1034/j.1600-0749.2000.130106.x. (Pubitemid 30184069)
36. Schallreuter KU, Wood JM, Pittelkow MR, et al. Increased monoamine oxidase A activity in the epidermis of patients with vitiligo. Arch Dermatol Res 1996;288:14-8, doi:10.1007/BF02505037. (Pubitemid 26009220)
37. Chu CY, Liu YL, Chiu HC, et al. Dopamine-induced apoptosis in human melanocytes involves generation of reactive oxygen species. Br J Dermatol 2006;154:1071-9, doi:10.1111/j.1365-2133.2006.07293.x.
38. Barisic-Drusko V, Rucevic I. Trigger factors in childhood psoriasis and vitiligo. Coll Antropol 2004;28:277-85. (Pubitemid 38901292)
39. Manolache L, Benea V. Stress in patients with alopecia areata and vitiligo. J Eur Acad Dermatol Venereol 2007;21:921-8, doi:10.1111/j.1468-3083. 2006.02106.x. (Pubitemid 47103722)
40. Picardi A, Pasquini P, Cattaruzza MS, et al. Stressful life events, social support, attachment security and alexithymia in vitiligo. A case-control study. Psychother Psychosom 2003;72:150-8, doi:10.1159/000069731. (Pubitemid 36469864)
41. Stojanovich L. Stress and autoimmunity. Autoimmun Rev 2010;9:A271-6, doi:10.1016/j.autrev.2009.11.014.
42. Tolis G, Stefanis C. Depression: biological and neuroendocrine aspects. Biomed Pharmacother 1983;37:316-22. (Pubitemid 14155668)
43. Stokes PE, Sikes CR. The hypothalamic-pituitary-adrenocortical axis in major depression. Endocrinol Metab Clin North Am 1988;17:1-19.
44. Slominski A, Wortsman J, Tuckey RC, et al. Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol 2007;265-6:143-9, doi:10.1016/j.mce.2006.12.012. (Pubitemid 46273958)
45. McGuire J. Adrenergic control of melanocytes. Arch Dermatol 1970;101:173-80, doi:10.1001/archderm.1970.04000020043007.
46. Bir LS, Aktan S. Sympathetic skin response in psoriasis and vitiligo. J Auton Nerv Syst 1999;77:68-71, doi:10.1016/S0165-1838(99)00030-2. (Pubitemid 29354169)
47. Schallreuter KU, Wood JM, Pittelkow MR, et al. Increased in vitro expression of beta 2-adrenoceptors in differentiating lesional keratinocytes of vitiligo patients. Arch Dermatol Res 1993;285:216-20, doi:10.1007/BF00372012. (Pubitemid 23210106)
48. Ekblad E, Edvinsson L, Wahlestedt C, et al. Neuropeptide Y coexists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept 1984;8:225-35, doi:10.1016/0167-0115(84)90064-8. (Pubitemid 14109276)
49. Joachim RA, Kuhlmei A, Dinh QT, et al. Neuronal plasticity of the "brain-skin connection": stress-triggered up-regulation of neuropeptides in dorsal root ganglia and skin via nerve growth factor-dependent pathways. J Mol Med 2007;85:1369-78, doi:10.1007/s00109-007-0236-8. (Pubitemid 350234092)
50. Aloe L, Bracci-Laudiero L, Alleva E, et al. Emotional stress induced by parachute jumping enhances blood nerve growth factor levels and the distribution of nerve growth factor receptors in lymphocytes. Proc Natl Acad Sci U S A 1994;91:10440-4, doi:10.1073/pnas.91.22.10440. (Pubitemid 24329013)
51. Tometten M, Klapp BF, Joachim R, et al. Nerve growth factor and its functional receptor TrkA are up-regulated in murine decidual tissue of stress-triggered and substance P-mediated abortion. Am J Reprod Immunol 2004;51:86-93, doi:10.1046/j.8755-8920.2003.00123.x. (Pubitemid 38190336)
52. Singh LK, Pang X, Alexacos N, et al. Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance P: a link to neurogenic skin disorders. Brain Behav Immun 1999;13:225-39, doi:10.1006/brbi.1998.0541. (Pubitemid 29450200)
53. Peters EM, Kuhlmei A, Tobin DJ, et al. Stress exposure modulates peptidergic innervation and degranulates mast cells in murine skin. Brain Behav Immun 2005;19:252-62, doi:10.1016/j.bbi.2004.08.005. (Pubitemid 40431540)
54. Peters EM, Handjiski B, Kuhlmei A, et al. Neurogenic inflammation in stress-induced termination of murine hair growth is promoted by nerve growth factor. Am J Pathol 2004;165:259-71, doi:10.1016/S0002-9440(10)63294-4. (Pubitemid 38821833)
55. Haas DA, George SR. Neuropeptide Y-induced effects on hypothalamic corticotropin-releasing factor content and release are dependent on noradrenergic/adrenergic neurotransmission. Brain Res 1989;498:333-8, doi:10.1016/0006-8993(89)91112-8. (Pubitemid 19228198)
56. Thorsell A. Brain neuropeptide Y and corticotropin-releasing hormone in mediating stress and anxiety. Exp Biol Med (Maywood) 2010;235:1163-7, doi:10.1258/ebm.2010.009331.
57. Dhillo WS, Small CJ, Jethwa PH, et al. Paraventricular nucleus administration of calcitonin gene-related peptide inhibits food intake and stimulates the hypothalamo-pituitary-adrenal axis. Endocrinology 2003;144:1420-5, doi:10.1210/en.2002-220902. (Pubitemid 36428484)
58. Brain SD, Williams TJ, Tippins JR, et al. Calcitonin gene-related peptide is a potent vasodilator. Nature 1985;313:54-6, doi:10.1038/313054a0. (Pubitemid 15192304)
59. Wahlestedt C, Edvinsson L, Ekblad E, et al. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J Pharmacol Exp Ther 1985;234:735-41. (Pubitemid 15247673)
60. Thorsell A, Heilig M. Diverse functions of neuropeptide Y revealed using genetically modified animals. Neuropeptides 2002;36:182-93, doi:10.1054/npep. 2002.0897.
61. Hanson ES, Dallman MF. Neuropeptide Y (NPY) may integrate responses of hypothalamic feeding systems and the hypothalamo-pituitary-adrenal axis. J Neuroendocrinol 1995;7:273-9, doi:10.1111/j.1365-2826.1995.tb00757.x.
62. Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007;13:803-11, doi:10.1038/nm1611. (Pubitemid 47038195)
63. Yehuda R, Brand S, Yang RK. Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. Biol Psychiatry 2006;59:660-3, doi:10.1016/j.biopsych.2005.08.027. (Pubitemid 43357961)
64. White BD, Dean RG, Edwards GL, et al. Type II corticosteroid receptor stimulation increases NPY gene expression in basomedial hypothalamus of rats. Am J Physiol 1994;266:R1523-9.
65. Colmers WF, El Bahh B. Neuropeptide Y and epilepsy. Epilepsy Curr 2003;3:53-8, doi:10.1046/j.1535-7597.2003.03208.x.
66. Bedoui S, von Horsten S, Gebhardt T. A role for neuropeptide Y (NPY) in phagocytosis: implications for innate and adaptive immunity. Peptides 2007;28:373-6, doi:10.1016/j.peptides.2006.07.029. (Pubitemid 46176264)
67. De la Fuente M, Del Rio M, Medina S. Changes with aging in the modulation by neuropeptide Y of murine peritoneal macrophage functions. J Neuroimmunol 2001;116:156-67, doi:10.1016/S0165-5728(01)00297-1. (Pubitemid 32588628)
68. Dimitrijevic M, Stanojevic S, Vujic V, et al. Effect of neuropeptide Y on inflammatory paw edema in the rat: involvement of peripheral NPY Y1 and Y5 receptors and interaction with dipeptidyl-peptidase IV (CD26). J Neuroimmunol 2002;129:35-42, doi:10.1016/S0165-5728(02)00173-X.
69. von Horsten S, Nave H, Ballof J, et al. Centrally applied NPY mimics immunoactivation induced by non-analgesic doses of met-enkephalin. Neuroreport 1998;9:3881-5, doi:10.1097/00001756-199812010-00021. (Pubitemid 29189320)
70. von Horsten S, Ballof J, Helfritz F, et al. Modulation of innate immune functions by intracerebroventricularly applied neuropeptide Y: dose and time dependent effects. Life Sci 1998;63:909-22, doi:10.1016/S0024-3205(98)00349-X. (Pubitemid 28392036)
71. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003;285:R277-97. (Pubitemid 36898897)
72. Schallreuter KU, Elwary SM, Gibbons NC, et al. Activation/deactivation of acetylcholinesterase by H2O2: more evidence for oxidative stress in vitiligo. Biochem Biophys Res Commun 2004;315:502-8, doi:10.1016/j.bbrc.2004.01.082. (Pubitemid 38183134)
73. Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991;97:1081-5, doi:10.1111/1523-1747.ep12492612.
74. Kannan S. Free radical theory of autoimmunity. Theor Biol Med Model 2006;3:22, doi:10.1186/1742-4682-3-22.
75. De la Fuente M, Bernaez I, Del Rio M, et al. Stimulation of murine peritoneal macrophage functions by neuropeptide Y and peptide YY. Involvement of protein kinase C. Immunology 1993;80:259-65. (Pubitemid 23308581)
76. Song C, Leonard BE. Comparison between the effects of sigma receptor ligand JO 1784 and neuropeptide Y on immune functions. Eur J Pharmacol 1998;345:79-87, doi:10.1016/S0014-2999(97)01592-6. (Pubitemid 28179474)
77. Levite M. Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. Proc Natl Acad Sci U S A 1998;95:12544-9, doi:10.1073/pnas.95.21.12544. (Pubitemid 28483801)
78. Levite M, Cahalon L, Hershkoviz R, et al. Neuropeptides, via specific receptors, regulate T cell adhesion to fibronectin. J Immunol 1998;160:993-1000. (Pubitemid 28049345)
79. Birol A, Kisa U, Kurtipek GS, et al. Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. Int J Dermatol 2006;45:992-3, doi:10.1111/j.1365-4632.2006.02744.x. (Pubitemid 44145043)
80. Tu CX, Gu JS, Lin XR. Increased interleukin-6 and granulocytemacrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo. J Dermatol Sci 2003;31:73-8, doi:10.1016/S0923-1811(02)00151-2.
81. Bedoui S, Kuhlmann S, Nave H, et al. Differential effects of neuropeptide Y (NPY) on leukocyte subsets in the blood: mobilization of B-1-like B-lymphocytes and activated monocytes. J Neuroimmunol 2001;117:125-32, doi:10.1016/S0165-5728(01)00328-9. (Pubitemid 32600075)
82. van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009;129:2220-32, doi:10.1038/jid.2009.32.
83. Wankowicz-Kalinska A, van den Wijngaard RM, Tigges BJ, et al. Immunopolarization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 2003;83:683-95. (Pubitemid 36618047)
84. Panuncio AL, Vignale R. Ultrastructural studies in stable vitiligo. Am J Dermatopathol 2003;25:16-20, doi:10.1097/00000372-200302000-00004. (Pubitemid 36133266)
85. Prignano F, Ricceri F, Bianchi B, et al. Dendritic cells: ultrastructural and immunophenotypical changes upon NB-UVB in vitiligo skin. Arch Dermatol Res 2011;303:231-8, doi:10.1007/s00403-010-1109-5.
86. Kroll TM, BommiasamyH, Boissy RE, et al. 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol 2005;124:798-806, doi:10.1111/j.0022-202X.2005. 23653.x. (Pubitemid 40489508)
87. Bedoui S, Lechner S, Gebhardt T, et al. NPY modulates epinephrine-induced leukocytosis via Y-1 and Y-5 receptor activation in vivo: sympathetic co-transmission during leukocyte mobilization. J Neuroimmunol 2002;132:25-33, doi:10.1016/S0165-5728(02)00278-3. (Pubitemid 35333322)
88. Sung CP, Arleth AJ, Feuerstein GZ. Neuropeptide Y upregulates the adhesiveness of human endothelial cells for leukocytes. Circ Res 1991;68:314-8.
89. Scholzen T, Armstrong CA, Bunnett NW, et al. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 1998;7:81-96, doi:10.1111/j.1600-0625.1998.tb00307.x. (Pubitemid 28210211)
90. Appelgren A, Appelgren B, Kopp S, et al. Neuropeptides in the arthritic TMJ and symptoms and signs from the stomatognathic system with special consideration to rheumatoid arthritis. J Orofac Pain 1995;9:215-25.
91. Baraniuk JN. Neurogenic mechanisms in rhinosinusitis. Curr Allergy Asthma Rep 2001;1:252-61, doi:10.1007/s11882-001-0016-4.
92. Pietrobon D. Migraine: new molecular mechanisms. Neuroscientist 2005;11:373-86, doi:10.1177/1073858405275554. (Pubitemid 41040865)
93. Misery L. Skin, immunity and the nervous system. Br J Dermatol 1997;137:843-50, doi:10.1111/j.1365-2133.1997.tb01542.x. (Pubitemid 28011122)
94. Levite M, Chowers Y. Nerve-driven immunity: neuropeptides regulate cytokine secretion of T cells and intestinal epithelial cells in a direct, powerful and contextual manner. Ann Oncol 2001;12 Suppl 2:S19-25, doi:10.1093/annonc/12.suppl-2.S19. (Pubitemid 33069682)
95. Vause CV, Durham PL. Calcitonin gene-related peptide differentially regulates gene and protein expression in trigeminal glia cells: findings from array analysis. Neurosci Lett 2010;473:163-7, doi:10.1016/j.neulet.2010.01.074.
96. Dallos A, Kiss M, Polyanka H, et al. Effects of the neuropeptides substance P, calcitonin gene-related peptide, vasoactive intestinal polypeptide and galanin on the production of nerve growth factor and inflammatory cytokines in cultured human keratinocytes. Neuropeptides 2006;40:251-63, doi:10.1016/j.npep.2006.06.002. (Pubitemid 44287033)
97. Hosoi J, Murphy GF, Egan CL, et al. Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. Nature 1993;363:159-63, doi:10.1038/363159a0. (Pubitemid 23147013)
98. Ding W, Stohl LL, Wagner JA, et al. Calcitonin gene-related peptide biases Langerhans cells toward Th2-type immunity. J Immunol 2008;181:6020-6.
99. Schallreuter KU, Moore J, Wood JM, et al. In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc 1999;4:91-6, doi:10.1038/sj.jidsp.5640189. (Pubitemid 29491263)
100. Kaludercic N, Takimoto E, Nagayama T, et al. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ Res 2010;106:193-202, doi:10.1161/CIRCRESAHA.109.198366.
101. Kim BJ, Jones HP. Epinephrine-primed murine bone marrow-derived dendritic cells facilitate production of IL-17A and IL-4 but not IFN-gamma by CD4+ T cells. Brain Behav Immun 2010;24:1126-36, doi:10.1016/j.bbi.2010.05.003.
102. Bai H, Cheng J, Gao X, et al. IL-17/Th17 promotes type 1 T cell immunity against pulmonary intracellular bacterial infection through modulating dendritic cell function. J Immunol 2009;183:5886-95, doi:10.4049/jimmunol.0901584.
103. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52:65-70, doi:10.1136/gut.52.1.65. (Pubitemid 36020767)
104. Nakae S, Nambu A, Sudo K, et al. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171:6173-7. (Pubitemid 37467240)
105. Seiderer J, Elben I, Diegelmann J, et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008;14:437-45, doi:10.1002/ibd.20339. (Pubitemid 351571823)
106. Wakashin H, Hirose K, Maezawa Y, et al. IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am J Respir Crit Care Med 2008;178:1023-32, doi:10.1164/rccm.200801-086OC.
107. Zhang Z, Zheng M, Bindas J, et al. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 2006;12:382-8, doi:10.1097/01.MIB.0000218764.06959.91.
108. Moseley TA, Haudenschild DR, Rose L, et al. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003;14:155-74, doi:10.1016/S1359- 6101(03)00002-9. (Pubitemid 36389528)
109. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004;21:467-76, doi:10.1016/j.immuni. 2004.08.018.
110. Sutton C, Brereton C, Keogh B, et al. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006;203:1685-91, doi:10.1084/jem.20060285. (Pubitemid 44036274)
111. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52, doi:10.1172/JCI5703. (Pubitemid 29218305)
112. Bassiouny DA, Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol 2011;36:292-7, doi:10.1111/j.1365-2230.2010.03972.x.
113. Dimitrov S, Lange T, Born J. Selective mobilization of cytotoxic leukocytes by epinephrine. J Immunol 2010;184:503-11, doi:10.4049/jimmunol. 0902189.
114. Basak PY, Adiloglu AK, Koc IG, et al. Evaluation of activatory and inhibitory natural killer cell receptors in non-segmental vitiligo: a flow cytometric study. J Eur Acad Dermatol Venereol 2008;22:970-6, doi:10.1111/j.1468-3083.2008.02681.x.
115. Yanagawa Y, Matsumoto M, Togashi H. Enhanced dendritic cell antigen uptake via alpha2 adrenoceptor-mediated PI3K activation following brief exposure to noradrenaline. J Immunol 2010;185:5762-8, doi:10.4049/jimmunol.1001899.
116. Watanabe M, Tomiyama-Miyaji C, Kainuma E, et al. Role of alpha-adrenergic stimulus in stress-induced modulation of body temperature, blood glucose and innate immunity. Immunol Lett 2008;115:43-9, doi:10.1016/j.imlet.2007.09.010. (Pubitemid 350298586)
117. Lechin F, van der Dijs B, Lechin AE, et al. Natural killer cells activity and neuroimmunological treatment of cancer. Clin Cancer Res 2004;10:8120, author reply 8120-1, doi:10.1158/1078-0432.CCR-04-1508.
118. Chin JH, Okazaki M, Hu ZW, et al. Activation of heat shock protein (hsp)70 and proto-oncogene expression by alpha1 adrenergic agonist in rat aorta with age. J Clin Invest 1996;97:2316-23, doi:10.1172/JCI118674. (Pubitemid 26165721)
119. Heneka MT, Gavrilyuk V, Landreth GE, et al. Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. J Neurochem 2003;85:387-98, doi:10.1046/j.1471-4159.2003.01694.x. (Pubitemid 36438334)
120. Meng X, Brown JM, Ao L, et al. Norepinephrine induces cardiac heat shock protein 70 and delayed cardioprotection in the rat through alpha 1 adrenoceptors. Cardiovasc Res 1996;32:374-83, doi:10.1016/0008-6363(96)00078-8. (Pubitemid 26246884)
121. Johnson JD, Campisi J, Sharkey CM, et al. Adrenergic receptors mediate stress-induced elevations in extracellular Hsp72. J Appl Physiol 2005;99:1789-95, doi:10.1152/japplphysiol.00390.2005. (Pubitemid 41547176)
122. Multhoff G, Mizzen L, Winchester CC, et al. Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. Exp Hematol 1999;27:1627-36, doi:10.1016/S0301-472X(99)00104-6.
123. Multhoff G, Botzler C, Wiesnet M, et al. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer 1995;61:272-9, doi:10.1002/ijc.2910610222.
124. Barreto A, Gonzalez JM, Kabingu E, et al. Stress-induced release of HSC70 from human tumors. Cell Immunol 2003;222:97-104, doi:10.1016/S0008-8749(03) 00115-1. (Pubitemid 36765431)
125. Moseley P. Stress proteins and the immune response. Immunopharmacology 2000;48:299-302, doi:10.1016/S0162-3109(00)00227-7.
126. Moseley PL. Heat shock proteins and the inflammatory response. Ann N Y Acad Sci 1998;856:206-13, doi:10.1111/j.1749-6632.1998.tb08327.x. (Pubitemid 28517351)
127. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002;20:395-425, doi:10.1146/annurev.immunol.20. 100301.064801. (Pubitemid 34293430)
128. Lehner T, Wang Y, Whittall T, et al. Functional domains of HSP70 stimulate generation of cytokines and chemokines, maturation of dendritic cells and adjuvanticity. Biochem Soc Trans 2004;32:629-32, doi:10.1042/BST0320629. (Pubitemid 39120401)
129. Asea A, Kraeft SK, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000;6:435-42, doi:10.1038/74697. (Pubitemid 30208161)
130. Campisi J, Fleshner M. Role of extracellular HSP72 in acute stress-induced potentiation of innate immunity in active rats. J Appl Physiol 2003;94:43-52. (Pubitemid 36014294)
131. Campisi J, Leem TH, Fleshner M. Stress-induced extracellular Hsp72 is a functionally significant danger signal to the immune system. Cell Stress Chaperones 2003;8:272-86, doi:10.1379/1466-1268(2003)008,0272:SEHIAF.2.0.CO;2. (Pubitemid 37484722)
132. Multhoff G, Botzler C, Jennen L, et al. Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J Immunol 1997;158:4341-50. (Pubitemid 127483936)
133. Niland B, Miklossy G, Banki K, et al. Cleavage of transaldolase by granzyme B causes the loss of enzymatic activity with retention of antigenicity for multiple sclerosis patients. J Immunol 2010;184:4025-32, doi:10.4049/jimmunol.0804174.
134. Le Poole IC, Luiten RM. Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun 2008;10:227-43, doi:10.1159/000131485.
135. Denman CJ, McCracken J, Hariharan V, et al. HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol 2008;128:2041-8, doi:10.1038/jid.2008.45. (Pubitemid 352001226)
136. Yuan ZQ, Zhang Y, Li XL, et al. HSP70 protects intestinal epithelial cells from hypoxia/reoxygenation injury via a mechanism that involves the mitochondrial pathways. Eur J Pharmacol 2010;643:282-8, doi:10.1016/j.ejphar. 2010.06.068.
137. Kawana K, Miyamoto Y, Tanonaka K, et al. Cytoprotective mechanism of heat shock protein 70 against hypoxia/reoxygenation injury. J Mol Cell Cardiol 2000;32:2229-37, doi:10.1006/jmcc.2000.1250. (Pubitemid 32039774)
138. Magalhaes J, Ascensao A, Soares JM, et al. Acute and severe hypobaric hypoxia increases oxidative stress and impairs mitochondrial function in mouse skeletal muscle. J Appl Physiol 2005;99:1247-53, doi:10.1152/japplphysiol.01324. 2004. (Pubitemid 43014326)
139. Tokyol C, Karaorman G, Bastug M. Effects of acute and adaptive hypoxia on heat shock protein expression in hepatic tissue. High Alt Med Biol 2005;6:247-55, doi:10.1089/ham.2005.6.247. (Pubitemid 41684305)
140. Renis M, Cardile V, Grasso S, et al. Switching off HSP70 and i-NOS to study their role in normal and H2O2-stressed human fibroblasts. Life Sci 2003;74:757-69, doi:10.1016/j.lfs.2003.07.016. (Pubitemid 37494902)
141. Calabrese V, Scapagnini G, Catalano C, et al. Regulation of heat shock protein synthesis in human skin fibroblasts in response to oxidative stress: role of vitamin E. Int J Tissue React 2001;23:127-35. (Pubitemid 33121153)
142. Scarparo AC, Visconti MA, de Oliveira AR, et al. Adrenoceptors in normal and malignant human melanocytes. Arch Dermatol Res 2000;292:265-7, doi:10.1007/s004030050485. (Pubitemid 30265053)
143. Johnson EM Jr, Gorin PD, Brandeis LD, et al. Dorsal root ganglion neurons are destroyed by exposure in utero to maternal antibody to nerve growth factor. Science 1980;210:916-8, doi:10.1126/science.7192014. (Pubitemid 11169851)
144. Levi-Montalcini R, Angeletti PU. Nerve growth factor. Physiol Rev 1968;48:534-69.
145. Meakin SO, Shooter EM. The nerve growth factor family of receptors. Trends Neurosci 1992;15:323-31, doi:10.1016/0166-2236(92)90047-C.
146. Chao MV, Hempstead BL. p75 and Trk: a two-receptor system. Trends Neurosci 1995;18:321-6, doi:10.1016/0166-2236(95)93922-K.
147. Levi-Montalcini R, Skaper SD, Dal Toso R, et al. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 1996;19:514-20, doi:10.1016/S0166-2236(96)10058-8. (Pubitemid 26359871)
148. Bischoff SC, Dahinden CA. Effect of nerve growth factor on the release of inflammatory mediators by mature human basophils. Blood 1992;79:2662-9.
149. Purcell WM, Atterwill CK. Mast cells in neuroimmune function: neurotoxicological and neuropharmacological perspectives. Neurochem Res 1995;20:521-32, doi:10.1007/BF01694534.
150. Torcia M, Bracci-Laudiero L, Lucibello M, et al. Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell 1996;85:345-56, doi:10.1016/S0092-8674(00)81113-7. (Pubitemid 26160706)
151. Torii H, Yan Z, Hosoi J, et al. Expression of neurotrophic factors and neuropeptide receptors by Langerhans cells and the Langerhans cell-like cell line XS52: further support for a functional relationship between Langerhans cells and epidermal nerves. J Invest Dermatol 1997;109:586-91, doi:10.1111/1523-1747.ep12337516. (Pubitemid 27433606)
152. Lambiase A, Bracci-Laudiero L, Bonini S, et al. Human CD4+ T cell clones produce and release nerve growth factor and express high-affinity nerve growth factor receptors. J Allergy Clin Immunol 1997;100:408-14, doi:10.1016/S0091- 6749(97)70256-2.
153. Garaci E, Caroleo MC, Aloe L, et al. Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV. Proc Natl Acad Sci U S A 1999;96:14013-8, doi:10.1073/pnas.96.24.14013.
154. Thorpe LW, Perez-Polo JR. The influence of nerve growth factor on the in vitro proliferative response of rat spleen lymphocytes. J Neurosci Res 1987;18:134-9, doi:10.1002/jnr.490180120.
155. Otten U, Ehrhard P, Peck R. Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci U S A 1989;86:10059-63, doi:10.1073/pnas.86.24.10059. (Pubitemid 20030775)
156. Kimata H, Yoshida A, Ishioka C, et al. Nerve growth factor specifically induces human IgG4 production. Eur J Immunol 1991;21:137-41, doi:10.1002/eji.1830210121.
157. Brodie C, Gelfand EW. Functional nerve growth factor receptors on human B lymphocytes. Interaction with IL-2. J Immunol 1992;148:3492-7.
158. Kemp EH, Emhemad S, Akhtar S, et al. Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo. Exp Dermatol 2011;20:35-40, doi:10.1111/j.1600-0625.2010.01181.x.
159. Kemp EH, Gawkrodger DJ, MacNeil S, et al. Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol 1997;109:69-73, doi:10.1111/1523-1747.ep12276556. (Pubitemid 27305651)
160. Kemp EH, Gawkrodger DJ, Watson PF, et al. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol 1997;109:495-500, doi:10.1046/j.1365-2249.1997.4781381.x. (Pubitemid 27402319)
161. Kemp EH, Gawkrodger DJ, Watson PF, et al. Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Clin Exp Immunol 1998;114:333-8, doi:10.1046/j.1365-2249.1998.00746.x. (Pubitemid 28539590)
162. Aloe L, Bracci-Laudiero L, Bonini S, et al. The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases. Allergy 1997;52:883-94, doi:10.1111/j.1398-9995.1997.tb01247.x.
163. Horigome K, Bullock ED, Johnson EM, Jr. Effects of nerve growth factor on rat peritoneal mast cells. Survival promotion and immediate-early gene induction. J Biol Chem 1994;269:2695-702.
164. Solomon A, Aloe L, Pe'er J, et al. Nerve growth factor is preformed in and activates human peripheral blood eosinophils. J Allergy Clin Immunol 1998;102:454-60, doi:10.1016/S0091-6749(98)70135-6. (Pubitemid 28471508)
165. Gawkrodger DJ, Ormerod AD, Shaw L, et al. Vitiligo: concise evidence based guidelines on diagnosis and management. Postgrad Med J 2010;86:466-71, doi:10.1136/pgmj.2009.093278.
166. Hossani-Madani AR, Halder RM. Topical treatment and combination approaches for vitiligo: new insights, new developments. G Ital Dermatol Venereol 2010;145:57-78.
167. Taher ZA, Lauzon G, Maguiness S, et al. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. Br J Dermatol 2009;161:654-9, doi:10.1111/j.1365-2133.2009.09217.x.
168. Grimbaldeston MA, Nakae S, Kalesnikoff J, et al. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 2007;8:1095-104, doi:10.1038/ni1503. (Pubitemid 47423757)
169. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006;4:754-9, doi:10.1016/j.cgh.2006.03.028. (Pubitemid 43841860)
170. Radakovic-Fijan S, Furnsinn-Friedl AM, Honigsmann H, et al. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol 2001;44:814-7, doi:10.1067/mjd.2001.113475. (Pubitemid 32391170)
171. Bai A, Lu N, Guo Y, et al. Modulation of inflammatory response via alpha2-adrenoceptor blockade in acute murine colitis. Clin Exp Immunol 2009;156:353-62, doi:10.1111/j.1365-2249.2009.03894.x.
172. Harmon RJ, Riggs PD. Clonidine for posttraumatic stress disorder in preschool children. J Am Acad Child Adolesc Psychiatry 1996;35:1247-9, doi:10.1097/00004583-199609000-00022. (Pubitemid 26282605)
173. Kinzie JD, Leung P. Clonidine in Cambodian patients with posttraumatic stress disorder. J Nerv Ment Dis 1989;177:546-50, doi:10.1097/00005053- 198909000-00005. (Pubitemid 19233931)
174. Stander S, Stander H, Seeliger S, et al. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. Br J Dermatol 2007;156:1020-6, doi:10.1111/j.1365-2133.2007. 07813.x. (Pubitemid 46642852)
175. Gupta MA, Guptat AK. The use of antidepressant drugs in dermatology. J Eur Acad Dermatol Venereol 2001;15:512-8, doi:10.1046/j.1468-3083.2001.00278.x.
176. Papadopoulos L, Bor R, Legg C. Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. Br J Med Psychol 1999;72(Pt 3):385-96, doi:10.1348/000711299160077. (Pubitemid 29465543)
177. Jin Y, Birlea SA, Fain PR, et al. Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J Invest Dermatol 2007;127:2558-62, doi:10.1038/sj.jid.5700953. (Pubitemid 47585070)
178. Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007;356:1216-25, doi:10.1056/NEJMoa061592. (Pubitemid 46465597)
179. Jin Y, Birlea SA, Fain PR, et al. Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. J Invest Dermatol 2011;131:1308-12.
180. Birlea SA, Jin Y, Bennett DC, et al. Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP. J Invest Dermatol 2011;131:371-81, doi:10.1038/jid.2010.337.
181. Spritz RA. The genetics of generalized vitiligo: autoimmune pathways and an inverse relationship with malignant melanoma. Genome Med 2010;2:78, doi:10.1186/gm199.
182. Spritz RA. Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease. Thyroid 2010;20:745-54, doi:10.1089/thy.2010. 1643.
183. Jin Y, Birlea SA, Fain PR, et al. Common variants in FOXP1 are associated with generalized vitiligo. Nat Genet 2010;42:576-8, doi:10.1038/ng.602.
184. Quan C, Ren YQ, Xiang LH, et al. Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet 2010;42:614-8, doi:10.1038/ng.603.
185. Ren Y, Yang S, Xu S, et al. Genetic variation of promoter sequence modulates XBP1 expression and genetic risk for vitiligo. PLoS Genet 2009;5:e1000523, doi:10.1371/journal.pgen.1000523.
186. Liang Y, Yang S, Zhou Y, et al. Evidence for two susceptibility loci on chromosomes 22q12 and 6p21-p22 in Chinese generalized vitiligo families. J Invest Dermatol 2007;127:2552-7, doi:10.1038/sj.jid.5700904. (Pubitemid 47585064)
187. Xu S, Zhou Y, Yang S, et al. Platelet-derived growth factor receptor alpha gene mutations in vitiligo vulgaris. Acta Derm Venereol 2010;90:131-5, doi:10.2340/00015555-0820.